Merck, GlaxoSmithKline earnings reflect product difficulties

Share this article:

Fourth quarter and full-year earnings were posted by Merck and GlaxoSmithKline today, and both companies suffered financial losses due to patent expiries, drug safety issues and ongoing litigation.

Merck reported a $531 million loss in the fourth quarter, due in part to $1.7 billion in costs related to vorapaxar, an experimental blood thinner. Merck halted one of two clinical studies on the drug in January, do to safety concerns. Full-year combined prescription drug sales for Merck and Schering-Plough were down 1% to $39.8 billion, from $40.1 billion in 2009, according to Merck's figures, created by adjusting the Schering-Plough merger completion date to January 2009, for a year-to-year comparison.

Merck's Singulair, Januvia, Janumet, Remicade and Isentress contributed a combined 15% growth year over year, CEO Ken Frazier said on a conference call this morning. Singulair, an asthma drug and Merck's best seller at almost $5 billion in global sales for 2010, will face patent expiration next year.

Frazier, told investors that the company would “remain committed to pursuing innovative R&D programs,” adding that boceprevir, an oral hepatitis C drug, and once-daily Janumet XR for diabetes, had been submitted for FDA approval. Boceprevir was granted an accelerated review by FDA in January.

GlaxoSmithKline's total sales were down 1% to $38.6 billion in 2010. The company continues to deal with ongoing litigation over bad marketing practices, and set aside an additional $3.4 billion to cover those costs in the fourth quarter. Additionally, GSK was dealt a blow by European and American regulators this year, when the company's blockbuster diabetes drug Avandia proved more dangerous than originally assumed. Avandia sales went down by 44% in 2010, ending the year at $713 million in global sales.

GSK's US pharmaceutical sales dropped by 11% in 2009, primarily due to Avandia sales and Valtrex's patent expiry. US Sales for Valtrex, a herpes treatment, plummeted to $408 million, a 73% decrease, according to GSK data.

In a note to investors today, Tim Anderson at Bernstein Research said Merck stock deserved an upgrade, “predicated on Merck being a comparatively good R&D organization, with a solid long-term R&D track record that hopefully foretells future new product flow that is meaningful.”

Regarding GSK's prospects, Anderson said in a separate note that “some traction is finally being made” with respect to the company's pipeline, which includes “several compounds having moved into phase III development.” Anderson said GSK's “nearest-term new product is likely to be Benlysta,” for lupus.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions